No Picture
News

Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020

SAN DIEGO, May 1, 2020 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that the location of its annual general meeting scheduled for May 12, 2020 at 8:00 am PDT has been moved to t… […]

No Picture
News

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

– Janssen’s DARZALEX FASPRO(TM) is a subcutaneous co-formulation of DARZALEX? and Halozyme’s ENHANZE? technology — Innovative, fixed-dose formulation demonstrates consistent efficacy to intravenous DARZALEX? with lower rate of infusion-related reactio… […]

No Picture
News

Halozyme Announces Janssen’s Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme’s ENHANZE® Technology For Patients With Multiple Myeloma

– Subcutaneous formulation can be administered in approximately five minutes, compared to multi-hour intravenous infusions –

SAN DIEGO, April 30, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen-Cilag Inte… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL- IND Filing for VK0214 in X-ALD on Track for Mid-Year- Balance Sheet R… […]

No Picture
News

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

SAN DIEGO, April 29, 2020 /PRNewswire/ — Amplyx Pharmaceuticals, a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced?that Ciara… […]